Feldman WB, Han J, Raymakers AJN, Furie GL, Chesebro BB - JAMA
- Research Publications
- Regulation and Clinical Evidence
Summary:
Between 2014 and 2024, the greenhouse gas emissions of asthma and COPD metered-dose inhalers in the US accounted for 98% of the estimated 24.9 million metric tons of CO₂-equivalent emissions during this period, equivalent to 530,000 gas-powered cars on the road each year. Policymakers and regulators should incentivize a shift toward dry powder and soft mist inhalers while facilitating market entry of affordable low-emission metered-dose products.
VIEW SOURCE
Recent Work from PORTAL
How Congress Can Fix Expert Advisory Committees
Daval CJR, Kesselheim AS - STAT
- Commentary & Opinion
- Regulation and Clinical Evidence
International Regulatory Status and Reimbursement Recommendations of Haematological Malignancy Drugs Withdrawn from the FDA Accelerated Approval Pathway
Mulsant SS, Kesselheim AS, Naci H - Journal of Cancer Policy
- Research Publications
- Price, Value, and Access
- Regulation and Clinical Evidence
Comments on FDA Discussion Paper, “Considerations for the Regulation of Generative AI-Enabled Medical Devices”
Jaiswal N, Gorijavolu R, Thomas S, Hwang TJ, Celi LA, Kesselheim AS - Food and Drug Administration (FDA)
- Policy Interactions
- Regulation and Clinical Evidence
Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115
©2026 Program On Regulation, Therapeutics, And Law (PORTAL). All rights reserved.